RT info:eu-repo/semantics/article
T1 Therapeutic strategies involving survivin inhibition in cancer
A1 Martínez García, David
A1 Manero Rupérez, Noemí
A1 Quesada Pato, Roberto
A1 Korrodi Gregório, Luís
A1 Soto Cerrato, Vanessa
K1 anticancer therapy
K1 apoptosis
K1 chemoresistance
K1 inhibitor ofapoptosis proteins
K1 SMAC mimetics
K1 survivin inhibitors
K1 Química orgánica
K1 Chemistry, Organic
AB Survivin is a small protein that belongs to the inhibitor of apoptosis protein family. It is abundantly expressed in tumors compared with adult differentiated tissues, being associated with poor prognosis in many human neoplasms. This apoptotic inhibitor has a relevant role in both the promotion of cancer cell survival and in the inhibition of cell death. Consequently, aberrant survivin expression stimulates tumor progression and confers resistance to several therapeutic strategies in a variety of tumors. In fact, efficient survivin downregulation or inhibition results in spontaneous apoptosis or sensitization to chemotherapy and radiotherapy. Therefore, all these features make survivin an attractive therapeutic target to treat cancer. Currently, there are several survivin inhibitors under clinical evaluation, although more specific and efficient survivin inhibitors are being developed. Moreover, novel combination regimens targeting survivin together with other therapeutic approaches are currently being designed and assessed. In this review, recent progress in the therapeutic options targeting survivin for cancer treatment is analyzed. Direct survivin inhibitors and their current development status are explored. Besides, the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated. Finally, promising novel inhibitors under preclinical or clinical evaluation as well as challenges of developing survivin inhibitors as a new therapy for cancer treatment are discussed.
PB Wiley
SN 0198-6325
YR 2019
FD 2019-05
LK http://hdl.handle.net/10259/5703
UL http://hdl.handle.net/10259/5703
LA eng
NO Consejería de Educación, Junta de Castilla y León. Grant Number: BU092U16 Instituto de Salud Carlos III. Grant Number: FIS PI18/00441
DS Repositorio Institucional de la Universidad de Burgos
RD 04-dic-2024